FDA Approved Brigatinib Drug For Lung Cancer Treatment

Cancers caused due to the abnormal proliferation of the cells in the lungs are referred to as Lung cancer. Around 3-5% of lung cancers are caused due to the changes in gene Anaplastic lymphoma kinase (ALK). Brigatinib drug receives approval from FDA to treat ALK-positive lung cancer as second-line therapy.
Email bookmark
Font : A-A+

Related Links